

Electronic Acknowledgement Receipt

EFS ID:	4700060
Application Number:	10524963
International Application Number:	
Confirmation Number:	3567
Title of Invention:	N-(-3-Methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl) pyridine-3- sulphonamide as an anticancer agent
First Named Inventor/Applicant Name:	David William Tonge
Customer Number:	44992
Filer:	Jacob G. Weintraub
Filer Authorized By:	
Attorney Docket Number:	100815-1P US
Receipt Date:	30-JAN-2009
Filing Date:	18-FEB-2005
Time Stamp:	22:54:02
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed (SB/08)	100815IDS1.pdf	1260268 8a9144c1fdbbf7b96a121b2f275c7636aa37a884	no	8

Warnings:

Information:

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

2	Information Disclosure Statement (IDS) Filed (SB/08)	100815IDS2.pdf	1157877 b171e99f2793a37c53b2b73c6cc349a9f81506a4	no	6
---	---	----------------	---	----	---

Warnings:

Information:

A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

3	NPL Documents	01BradburyJMedChem1997996 100440.PDF	1888642 8b35dcf9eb6f367938ca09b4e570108dbda da696	no	9
---	---------------	---	---	----	---

Warnings:

Information:

4	NPL Documents	02Brooks2008abstract.PDF	130964 c2ac0a4271625745510eb8be5572dd06f36 c840b	no	1
---	---------------	--------------------------	--	----	---

Warnings:

Information:

5	NPL Documents	03CarducciClinCancerRes20066 296s6300s12.PDF	1173651 c8ade1741be2ab26958e1391fc57f9eeda01 56a1	no	5
---	---------------	---	---	----	---

Warnings:

Information:

6	NPL Documents	04CarducciAscoAbstracts2001. PDF	174600 d432c0eef5466bd143ad3cdf02994a7e627 1a20a	no	2
---	---------------	-------------------------------------	--	----	---

Warnings:

Information:

7	NPL Documents	05Carragher2008abstractB77. PDF	99407 a4296d0d7f2f16031892c904e4f7f815f9e66 7f0	no	1
---	---------------	------------------------------------	---	----	---

Warnings:

Information:

8	NPL Documents	06ChiaoBritishJournalofCancer 2000360365833.PDF	972254 0f1ad429a6ffb4c4a7deb8becc8a2392513 23dc	no	6
---	---------------	--	---	----	---

Warnings:

Information:

9	NPL Documents	07ChirgwinJMuscNeuronInteract200430831843.PDF	2214235	no	11
			abfe285164ff01f6a52740c77448f2ae09d35d71		
Warnings:					
Information:					
10	NPL Documents	08ClarksonJonesDrugMetabRev200820640supp3abs283.PDF	160023	no	1
			0f31d97ef0dd023fb020a1b84df4b3fbc361cba		
Warnings:					
Information:					
11	NPL Documents	09ClarksonJones2008poster.PDF	310484	no	1
			2d9cbea5641617bc23cdfd0d23bdc1164f1250d6		
Warnings:					
Information:					
12	NPL Documents	10CurwenMolCancerTher2007612SuppllabsA272.PDF	492314	no	2
			13fe5ccd9a90e6d818e28fd39c2809f70c3c7cc6		
Warnings:					
Information:					
13	NPL Documents	11Curwen2007poster.PDF	802283	no	1
			ccb2fe891cc57c851a57a965c6daf011a29b1498		
Warnings:					
Information:					
14	NPL Documents	12Curwen2007oralpresentation.PDF	3348300	no	10
			ccc93e94681558371a090189778175cb9035c6da		
Warnings:					
Information:					
15	NPL Documents	15Dawson2008oralpresentation.PDF	1897749	no	17
			e6435726a48490a2328ab0516e519747a6801245		
Warnings:					
Information:					
16	NPL Documents	16Dawson2008GenitourinaryCancersSympabst7.PDF	81758	no	1
			abd3b6603281ea182d2104221d6d04721d496e3b		
Warnings:					
Information:					
17	NPL Documents	17Dawson2008poster.PDF	482370	no	1
			a37afc2a788a673cd5659d36dd5c451cb04a9261		
Warnings:					
Information:					

18	NPL Documents	18DingemanseBrJClinPharmacol200235536253.PDF	1268739	no	8
			0cf136ceba6618ef37c4821dc95e8ebb26074c50		
Warnings:					
Information:					
19	NPL Documents	19FizaziAscoAbstracts2001.PDF	137370	no	1
			fa7d406cc37dc7fb4ad31ea747181ee91fbeeabb		
Warnings:					
Information:					
20	NPL Documents	13Curwen2007posterItaly.PDF	1575379	no	1
			bdfb3e837f9605f28083012056e58b1649b8dd60		
Warnings:					
Information:					
21	NPL Documents	14DawsonCurrentTreatOptionsOncol20081051079suppl1.PDF	118723	no	4
			cc1e89e2af187ee787c4774e5bbcef72a4e0599b		
Warnings:					
Information:					
22	NPL Documents	20GodaraUrology2007209215701.PDF	3718148	no	7
			2e80c8a1d14e395896860117ef5ebed6cf3d0979		
Warnings:					
Information:					
23	NPL Documents	21GodaraTheProstate2005273465.PDF	1474743	no	8
			ccf36ba1c8feef1f274834c3d48fc3a8dc33acd58		
Warnings:					
Information:					
24	NPL Documents	22GrossGoupilEuropeanUrologySupp20091141198.PDF	1106014	no	6
			6d06abc4192e535defe9780ebac351baec3d4a49		
Warnings:					
Information:					
25	NPL Documents	23Growcott2008ManchesterPoster.PDF	723436	no	1
			bc6d5b4edf3482726d1460e28d172da00acb5df1		
Warnings:					
Information:					
26	NPL Documents	24Growcott2007ItalyPoster.PDF	1017966	no	1
			cd1647003ccb4b9462828388b0cf59188d1cf06c		
Warnings:					
Information:					

27	NPL Documents	25Growcott2007Italyoralpresen tation.PDF	553475	no	3
			0f94985e3efef59129bbc463fcc3875d05dc 1014		
Warnings:					
Information:					
28	NPL Documents	26GrowcottMolCancerTher200 7612SupplIAbsB269.PDF	254002	no	1
			3021822d112b773481e8a45e8aff7bd489a 466cf		
Warnings:					
Information:					
29	NPL Documents	27Growcott2007ACCRPoster. PDF	324205	no	1
			5565f94d2be5e79e5f016dfd5f59435bef26 dde0		
Warnings:					
Information:					
30	NPL Documents	28GrowcottAnticancerdrugs20 0900000000.PDF	1097344	no	6
			5a64bafef49e767575601026516d2e1693f5 0147		
Warnings:					
Information:					
31	NPL Documents	29GuiseAscoAbstracts2001.PDF	106744	no	1
			666377eb2eb638b31f5cbc8363efcb4dea8 255d9		
Warnings:					
Information:					
32	NPL Documents	30HickinsonProcAmAssocCanc erRes200849abs1487.PDF	139471	no	2
			d3b17fe97f5d8816f9d3300caa2de409e18b 20c7		
Warnings:					
Information:					
33	NPL Documents	31Hickinson2008poster.PDF	352000	no	1
			b54fe88ea4ddad4caada9adf3ad792db50c c4a03		
Warnings:					
Information:					
34	NPL Documents	32Isherwood2008poster.PDF	669008	no	1
			6eae82f8bae8a78a755fb693fb3bdd5dea5c 3b39		
Warnings:					
Information:					
35	NPL Documents	33James2007absO2.PDF	152939	no	3
			dc2787e39bd62584f583f6b773cb3a96f72c 92dd		
Warnings:					
Information:					

36	NPL Documents	34James2008oralpresentation.PDF	1183066	no	14
			11af0e6c89157ee8f41ff228d275c134dc53b5ddc		
Warnings:					
Information:					
37	NPL Documents	35James2007abstractP10.PDF	151055	no	2
			d63bfe4a7219c2ada7bdbcb1bce3b7ceb6e95ee11		
Warnings:					
Information:					
38	NPL Documents	36James2007SpainPoster.PDF	307920	no	1
			9b852553e4958ab141e3f5ef609c1e95202e5e25		
Warnings:					
Information:					
39	NPL Documents	37James2007oralpresentation.PDF	3286330	no	19
			2772ee3854e8fea6195e8f769c1ee61e1e4a2c55		
Warnings:					
Information:					
40	NPL Documents	38JamesEurUrol2008.PDF	3637069	no	12
			d3da2abb3e060e56b86504378408a100178c4114		
Warnings:					
Information:					
41	NPL Documents	39JamesEuropeanJournalofCancerSupp2007abs3LB.PDF	156708	no	1
			6850a4897f08ecf49c90028427a8a5f0705214b1		
Warnings:					
Information:					
42	NPL Documents	40Kenyon2007poster.PDF	823139	no	1
			3eb2a713641773e257c0c05a47f0e9b2cb2c9cf7		
Warnings:					
Information:					
43	NPL Documents	41KnightProcAmAssocCancerRes200748abs1135.PDF	136819	no	2
			1d820f79958e5e6dfdcd8492bbe69565350e7604c		
Warnings:					
Information:					
44	NPL Documents	42KnightAACR2007Poster.PDF	1220442	no	1
			6aa442713521273ed35c8fef7cfd675b65e03a40		
Warnings:					
Information:					

45	NPL Documents	43KnightIntJournalofo 200946547134.PDF	2357127	no	7
			3084a395f972da3c5e7973b18296f5b082af d655		
Warnings:					
Information:					
46	NPL Documents	44KopetzInvestNewDrugs2002 17318220options1.pdf	559946	no	10
			8d9362a04d7e5cd6da35ca9fa162a328baa ab9d2		
Warnings:					
Information:					
47	NPL Documents	45Mohammad20051213a.PDF	80045	no	1
			c563b2fb9fd39055e8ade06cbcd8d0dac3 291c8		
Warnings:					
Information:					
48	NPL Documents	46NelsonNeoplasia2005631637 77abstract.PDF	1372734	no	7
			220080f08c0d3ff83cd5ab50514d4e190f1e 60ac		
Warnings:					
Information:					
49	NPL Documents	47NelsonNatureReviewsCancer 20031101163.PDF	1640641	no	7
			0d55a257dd000127df26a48a613a8d0ae0e 4c77b		
Warnings:					
Information:					
50	NPL Documents	48NelsonAscoAbstracts2001. PDF	116298	no	1
			a863c5f1546d05b67286d53445d483df832 66015		
Warnings:					
Information:					
51	NPL Documents	49Payne2008oralpresentation. PDF	1676065	no	15
			ec7abf9409cce26ecb8b66ce42af8d5cb5a5 8c20		
Warnings:					
Information:					
52	NPL Documents	50PflugMolCancerTher2007612 SuppllabsA287.PDF	500796	no	2
			5107b803cf6e57417c3010bdbf669dcd26 b8bd4		
Warnings:					
Information:					
53	NPL Documents	51RansonEurJCancerSuppl200 711211354abs718.PDF	495789	no	2
			53ccfa5c6f9fe1b18669fc00b2773eacea620 7f7		
Warnings:					
Information:					

54	NPL Documents	52Ranson2007Poster.PDF	288466	no	1
			dad87e8ef6ba59853f620702b897023681fa940e		
Warnings:					
Information:					
55	NPL Documents	53RosanoEurJCancerSupp2008546Abs168.PDF	260636	no	1
			c2e63636595a363cf7598370b65fa5525d79a3a2		
Warnings:					
Information:					
56	NPL Documents	54RosanoProcAmAssocCancerRes200849abs2574.PDF	136598	no	2
			8825c91b40a439f2bcdfa9178a7d5a9ff2691260		
Warnings:					
Information:					
57	NPL Documents	55Rosano2008presentation.PDF	9440122	no	16
			bea5d288c60e1def31403c238dc119159d5fb32c		
Warnings:					
Information:					
58	NPL Documents	56RosanoAACR2007abstract5636.PDF	135832	no	2
			8261aab728b691a958ece847afcce4b493d320f6		
Warnings:					
Information:					
59	NPL Documents	57RosanoClinScience2002306S309S103supp48.PDF	630312	no	4
			851f5c93a1fac330ecafef94bb9ab62154e94ab5		
Warnings:					
Information:					
60	NPL Documents	58RosanoAAC2008abstractPR15.PDF	107687	no	2
			9edf77f234ddfab39117905ca12a2762acfe8245		
Warnings:					
Information:					
Total Files Size (in bytes):			62138527		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.